Researchers at Baylor College of Medicine have discovered a potential new strategy to fight back against Alzheimer’s and Parkinson’s diseases, conditions that are linked to the toxic accumulation of Tau and alpha synuclein protein clumps in the brain. The team reports in Nature Communications that tubulin, the building block of microtubules, the cell’s internal ‘railway tracks,” can stop Tau and alpha synuclein from forming toxic clumps and instead steer them into their normal, healthy roles.

“Tau and alpha synuclein are well known for their roles in neurodegenerative diseases like Alzheimer’s and Parkinson’s...

Northwestern University engineers have developed the first modular robots with athletic intelligence. They can be combined and recombined in the wild, recover from injury and keep moving no matter what’s thrown at them.

Called “legged metamachines,” the creations are made from autonomous, Lego-like modules that snap together into an endless number of configurations. Each module by itself is a complete robot with its own motor, battery and computer. Alone, a module can roll, turn and jump. But the real agility and indestructibility emerges when the modules combine.

The study was published i...

Look up on a clear night and you’ll see the streaks of our new space age. What you don’t see is the growing fallout for the atmosphere that keeps us alive.

A wave of satellite launches and reentries is changing the chemistry and physics of the middle and upper atmosphere.

Studies warn of ozone depletion, stratospheric heating and new metal aerosols from burning spacecraft. The pace is accelerating fast and unless we redesign how we use and retire satellites, we risk swapping one environmental problem (congestion in Earth orbit from too many spacecraft) for another (an atmosphere seeded with rocket soot and satellite ash).

The problem is that most satellites are de-orbited when they reach the end of their lives...

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes and obesity is independently associated with a significantly increased five-year risk for osteoporosis, gout, and osteomalacia compared with nonuse, according to a study presented at the annual meeting of the American Academy of Orthopaedic Surgeons, held from March 2 to 6 in New Orleans.

Muaaz Wajahath, from the Michigan State University College of Human Medicine in East Lansing, and colleagues evaluated the five-year risk for osteoporosis, gout, and osteomalacia in adults with both type 2 diabetes and obesity treated with GLP-1 RAs (semaglutide, liraglutide, dulaglutide, or exenatide) compared with matched controls (73,483 per group).

The researchers found that at five years, patients expo...